AQR Capital Management LLC decreased its holdings in shares of PetIQ, Inc. (NASDAQ:PETQ - Free Report) by 17.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 266,508 shares of the company's stock after selling 54,650 shares during the quarter. AQR Capital Management LLC owned approximately 0.90% of PetIQ worth $5,879,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of PETQ. Goldman Sachs Group Inc. increased its holdings in shares of PetIQ by 11.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,036,292 shares of the company's stock worth $20,467,000 after acquiring an additional 108,870 shares during the period. ProShare Advisors LLC raised its holdings in shares of PetIQ by 119.6% during the first quarter. ProShare Advisors LLC now owns 173,453 shares of the company's stock valued at $3,171,000 after buying an additional 94,453 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in PetIQ by 196.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 129,632 shares of the company's stock worth $2,370,000 after buying an additional 85,920 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of PetIQ by 105.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 140,660 shares of the company's stock worth $2,571,000 after purchasing an additional 72,187 shares in the last quarter. Finally, Boston Partners raised its position in shares of PetIQ by 6.8% during the 1st quarter. Boston Partners now owns 1,067,677 shares of the company's stock worth $19,124,000 after buying an additional 67,797 shares in the last quarter. Institutional investors own 94.99% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on PETQ shares. William Blair cut shares of PetIQ from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 7th. Truist Financial lowered shares of PetIQ from a "buy" rating to a "hold" rating and lifted their price target for the stock from $30.00 to $31.00 in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.67.
Check Out Our Latest Report on PetIQ
PetIQ Stock Up 0.1 %
NASDAQ:PETQ traded up $0.03 on Friday, hitting $30.87. 292,383 shares of the company's stock traded hands, compared to its average volume of 480,174. The company has a market cap of $922.70 million, a PE ratio of 140.32 and a beta of 1.73. The company has a current ratio of 2.58, a quick ratio of 1.68 and a debt-to-equity ratio of 1.68. The firm has a 50-day moving average price of $29.30 and a 200-day moving average price of $23.03. PetIQ, Inc. has a 1 year low of $15.09 and a 1 year high of $30.89.
PetIQ (NASDAQ:PETQ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.20. The business had revenue of $328.90 million for the quarter, compared to the consensus estimate of $330.14 million. PetIQ had a net margin of 1.20% and a return on equity of 18.75%. PetIQ's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 earnings per share. Equities analysts anticipate that PetIQ, Inc. will post 1.15 EPS for the current fiscal year.
PetIQ Company Profile
(
Free Report)
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
Read More
Before you consider PetIQ, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetIQ wasn't on the list.
While PetIQ currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
